JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.

"Conflict of Interest Disclosures Suresh S. Ramalingam received grant funding and/or other support (for consultancy) from Amgen, AstraZeneca, Bristol‐Myers Squibb, Merck, Takeda, Tesaro, Advaxis, AbbVie, and Genentech/Roche. Mark M. Awad received grant funding and/or personal fees from AstraZeneca, Bristol‐Myers Squibb, Genentech, Ariad, Blueprint Medicine, Gritstone, Maverick, Merck, Nektar, Syndax, and Lilly. Afshin Dowlati received grant funding (to the institution) and/or personal fees (for consultancy) from Bayer, Bristol‐Myers Squibb, Eli Lilly, EMD Serono, Incuron, Ipsen, Mirati, Regeneron, Roche, Takeda, Tesaro, United Therapeutics, Vertex, AbbVie, AstraZeneca, Millenium, Seattle Genetics, and Ariad. Thomas E. Stinchcombe received personal fees (for advisory boards) from AstraZeneca, EMD Serono, Foundation Medicine, G1 Therapeutics, Genentech/Roche, Lilly Oncology, Novartis, and Takeda and grant funding (to the institution) from Advaxis, AstraZeneca, Blueprint Medicines, Genentech/Roche, Merck, Regeneron, and Takeda. Grace K. Dy received personal fees (for consultancy) from GlaxoSmithKline. David R. Spigel received research grant funding from, and had a consulting and/or advisory role (with or without funds to the institution) with, AstraZeneca, Bristol‐Myers Squibb, Celgene, EMD Serono, Genentech/Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Nektar, Takeda, AbbVie, Amgen, Aptitude Health, Bayer, Boehringer Ingelheim, Dracen Pharmaceuticals, Evelo Therapeutics, Foundation Medicine, Iksuda Therapeutics, Illumina, Intellisphere, Moderna Therapeutics, Molecular Templates, PharmaMar, Precision Oncology, Seattle Genetics, TRIPTYCH Health Partners, TRM Oncology, Aeglea Biotherapeutics, Astellas Pharma, BIND Therapeutics, Celldex, Clovis Oncology, Daiichi Sankyo, Eisai, G1 Therapeutics, GRAIL, ImClone Systems, Ipsen, Janssen, MedImmune, Neon Therapeutics, Tesaro, Transgene, and University of Texas Southwestern Medical Center‐Simmons Cancer Center. Nithya Iyer Singh is an employee of GlaxoSmithKline. Yongqiang Tang is an employee of GlaxoSmithKline. Sharon Lu is an employee of GlaxoSmithKline. Iryna Teslenko was an employee of GlaxoSmithKline at the time of this work and holds stocks and/or shares in GlaxoSmithKline. The other authors made no disclosures."

"GlaxoSmithKline 10.13039/100004330"

"This trial is registered at ClinicalTrials.gov (NCT04475939)."